Discover
MGX
Metagenomi Therapeutics, Inc.
1.10
2 x 0.83
2 x 1.48
bid
ask
-
0.03
2.65%
2 @ 04:00 PM
1.10 +0.00 (0.00%)
| Ytd | -32.10% | |
| 1y | -48.60% |
1.10
day range
1.14
1.10
52 week range
3.95
| Open | 1.12 | Prev Close | 1.13 | Low | 1.10 | High | 1.14 | Mkt Cap | 41.55M |
| Vol | 124.38K | Avg Vol | 162.38K | EPS | -2.49 | P/E | N/A | Forward P/E | -1.38 |
| Beta | 0.67 | Short Ratio | 0.60 | Inst. Own | 34.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.21 | 200-d Avg | 1.41 | 1yr Est | 18.40 |
| Income Statement | |||
| Total Revenue | -257.00K | ||
| Revenues (USD) | -257.00K | ||
| Gross Profit | -257.00K | ||
| Operating Expenses | 28.52M | ||
| Research and Development Expense | 22.51M | ||
| Selling, General and Administrative Expense | 6.00M | ||
| Operating Income | -28.77M | ||
| Net Income | -27.48M | ||
| Net Income Common Stock | -27.48M | ||
| Net Income Common Stock (USD) | -27.48M | ||
| Consolidated Income | -27.48M | ||
| Earnings per Basic Share | -0.73 | ||
| Earnings per Basic Share (USD) | -0.73 | ||
| Earnings per Diluted Share | -0.73 | ||
| Earning Before Interest & Taxes (EBIT) | -27.48M | ||
| Earning Before Interest & Taxes (USD) | -27.48M | ||
| Weighted Average Shares | 37.66M | ||
| Weighted Average Shares Diluted | 37.66M | ||
| Balance Sheet | |||
| Cash and Equivalents | 43.42M | ||
| Cash and Equivalents (USD) | 43.42M | ||
| Investments | 83.79M | ||
| Investments Current | 81.64M | ||
| Investments Non-Current | 2.15M | ||
| Current Assets | 124.47M | ||
| Property, Plant & Equipment Net | 41.67M | ||
| Total Assets | 173.70M | ||
| Debt Current | 6.24M | ||
| Total Debt | 37.72M | ||
| Current Liabilities | 27.63M | ||
| Debt Non-Current | 31.49M | ||
| Total Liabilities | 61.13M | ||
| Accumulated Retained Earnings (Deficit) | -361.41M | ||
| Accumulated Other Comprehensive Income | -122.00K | ||
| Shareholders Equity | 112.57M | ||
| Shareholders Equity (USD) | 112.57M | ||
| Assets Non-Current | 49.23M | ||
| Total Debt (USD) | 37.72M | ||
| Deferred Revenue | 11.20M | ||
| Liabilities Non-Current | 33.50M | ||
| Trade and Non-Trade Payables | 2.60M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.62M | ||
| Net Cash Flow from Financing | 67.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 13.72M | ||
| Capital Expenditure | -125.00K | ||
| Issuance (Purchase) of Equity Shares | 74.00K | ||
| Issuance (Repayment) of Debt Securities | -7.00K | ||
| Net Cash Flow from Investing | 33.17M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 33.29M | ||
| Net Cash Flow from Operations | -19.51M | ||
| Share Based Compensation | 2.27M | ||